ВОЗМОЖНОСТЬ И НЕОБХОДИМОСТЬ КАТЕТЕРНОЙ АБЛАЦИИ СУБСТРАТА ЖЕЛУДОЧКОВЫХ АРИТМИЙ У ПАЦИЕНТОВ С ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА И ИМПЛАНТИРОВАННЫМИ КАРДИОВЕРТЕРАМИДЕФИБРИЛЛЯТОРАМИ
https://doi.org/10.24884/0042-4625-2013-172-2-020-024
Аннотация
The article describes the data of efficiency of catheter ablation of substrate of ventricular arrhythmias, performed in patients with ischemic heart disease and implanted cardioverter- defibrillator (ICD) in order to decrease the number of ICD therapy. An assessment of the follow-up study of 32 patients was made, the catheter ablations were performed in 10 of them. The statistically reliable number of ICD therapy and at the same time both «shock» and antitachycardia pacing decreased in the group of catheter ablation.
Об авторах
Григорий Алексеевич Громыко
Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова
Россия
Россия
Сергей Михайлович Яшин
Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова
Россия
Россия
Евгений Викторович Лян
Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова
Россия
Россия
Александр Игоревич Казаков
Санкт-Петербургский государственный медицинский университет им. акад. И. П. Павлова
Россия
Россия
Список литературы
1. Рекомендации Всероссийского научного общества аритмологов. М., 2009.
2. The antiarrhythmics versus implantable defibrillators (avid) investigators. a comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias // N. Engl. J. Med. 1997. Vol. 337. P. 1576–1584.
3. Aliot E. M., Stevenson W. G., Almendral-Garrote J. M. et al. EHRA/HRS expert consensus on catheter ablation of ventricular arrhy thmias // Heart Rhythm. 2009. Vol. 6. Issue 6. P. 886–933.
4. Bardy G. H., Lee K. L., Mark D. B. et al. For the sudden cardiac death in heart failure trial (scd-hft)investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure // N. Engl. J. Med. 2005. Vol. 352. P. 225–237.
5. Bunch T. J., Mahapatra S., Madhu Reddy Y., Lakkireddy D. The role of percutaneous left ventricular assist devices during ventricular tachycardia ablation // Europace. 2012. Vol. 14. Suppl. 2. P. 26–32.
6. Connolly S. J., Gent M., Roberts R. S. et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone // Circulation. 2000. Vol. 101. P. 1297–1302.
7. Della Bella P., Riva S., Fassini G. et al. Incidence and significance of pleomorphism in patients with postmyocardial infarction ventricular tachycardia. Acute and long-term outcome of radiofrequency catheter ablation // Eur. Heart. J. 2004 Vol. 25. P. 1127–1138.
8. Kuck K. H., Cappato R., Siebels J., Rüppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the cardiac arrest study Hamburg (CASH) // Circulation. 2000 Vol. 102. P. 748–754.
9. Kuck K. H., Schaumann A., Eckardt L. et al. VTACH study group. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial // Lancet. 2010. Vol. 375, № 9708. P. 31–40.
10. Mitchell L. B., Pineda E. A., Titus J. L. et al. Sudden death in patients with implantable cardioverter defibrillators: the importance of post-shock electromechanical dissociation // J. Am. Coll. Cardiol. 2002 Vol. 39, № 8. P. 1323–1328.
11. Moss A. J., Zareba W., Hall W. J. et al. The multicenter automatic defibrillator implantation trial II investigators. Prophylactic im plan tation of a defibrillator in patients with myocardial infarction and reduced ejection fraction // N. Engl. J. Med. 2002. Vol. 346. P. 877–883.
12. Poole J. E., Johnson G. W., Hellkamp A. S. et al. Prognostic impor tance of defibrillator shocks in patients with heart failure // N. Engl. J. Med. 2008 Vol. 359. P. 1009–1017.
13. Reddy V. Y., Reynolds M. R., Neuzil P. et al. Prophylactic catheter ablation for the prevention of defibrillator therapy // N. Engl. J. Med. 2007. Vol. 357. P. 2657–2665.
14. Schron E. B., Exner D. V., Yao Q. et al. Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks // Circulation. 2002 Vol. 105. P. 589–594.
15. Tanner H., Hindricks G., Volkmer M. et al. Catheter ablation of recurrent scar-related ventricular tachycardia using electroanatomical mapping and irrigated ablation technology: results of the prospective multicenter Euro-VT-study // J. Cardiovasc. Electrophysiol. 2010. Vol. 21. P. 47–53.
16. Volkmer M., Ouyang F., Deger F. et al. Substrate mapping vs. tachycardia mapping using CARTO in patients with coronary artery disease and ventricular tachycardia: impact on outcome of catheter ablation // Europace. 2006. Vol. 8. P. 968–976.
17. Zipes D. P., Camm A. J., Borggrefe M. et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death // Circulation. 2006. Vol. 114. P. 1088–1132.
Рецензия
Для цитирования:
Громыко Г.А., Яшин С.М., Лян Е.В., Казаков А.И. ВОЗМОЖНОСТЬ И НЕОБХОДИМОСТЬ КАТЕТЕРНОЙ АБЛАЦИИ СУБСТРАТА ЖЕЛУДОЧКОВЫХ АРИТМИЙ У ПАЦИЕНТОВ С ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА И ИМПЛАНТИРОВАННЫМИ КАРДИОВЕРТЕРАМИДЕФИБРИЛЛЯТОРАМИ. Вестник хирургии имени И.И. Грекова. 2013;172(2):020-024. https://doi.org/10.24884/0042-4625-2013-172-2-020-024
For citation:
Gromyko G.A., Yashin S.M., Lyan E.V., Kazakov A.I. POSSIBILITY AND NECESSITY OF CATHETER ABLATION OF VENTRICULAR ARRHYTHMIAS IN PATIENTS WITH ISCHEMIC HEART DISEASE AND IMPLANTED CARDIOVERTERDEFIBRILLATOR. Grekov's Bulletin of Surgery. 2013;172(2):020-024. (In Russ.) https://doi.org/10.24884/0042-4625-2013-172-2-020-024
Просмотров: 248
Послать статью по эл. почте 
